Trusted Everolimus Drug + Bioabsorbable Polymer

Unlike permanent polymer DES technology, in SYNERGY^TM stent Bioabsorbable Polymer is gone shortly after the drug is completely eluted.

Kang Network Meta-Analysis

SYNERGY^TM Stent ranked #1 for the lowest relative risk of def/prob ST at 1-year¹.

Real-World SCAAR Registry

Lowest ST rate compared to newer generation DES despite use in patients with statistically more Class B2/C lesions, diabetes, prior PCI, and 3VD².

Syntax II Trial

The SYNTAX II Trial utilizing SYNERGY^TM Stent, physiological assessment, IVUS guidance, and contemporary state-of-the-art PCI techniques, demonstrated equivalent outcomes to CABG in patients with three-vessel disease at 2-years³.

Consistent CTO Study

The SYNERGY^TM Stent combined with up-to-date techniques demonstrated low event rates in complex lesions (mean stent length 85.6 mm, JCTO Score 2.4) and very symptomatic patients at 12-months⁴.

EVOLVE Short DAPT Trial^†*

Studying 3-month DAPT in high bleeding risk patients^†*

SENIOR Trial

Studying 1-month DAPT in elderly patients^‡§

ASET Trial

Studying 0-month DAPT in patients with chronic stable angina^ࠠ